What Happens When You Stop Semaglutide? What the Research Actually Found

People stop GLP-1 medicines for different reasons: side effects, cost, access, pregnancy planning, personal goals, a change in treatment plan or medical advice. (In a 2026 interview study, participants' reasons for stopping included side effects, cost and pregnancy.) A big question follows: what happens to weight and health afterward?

One frequently cited source is the STEP 1 trial extension, which followed a subset of participants after they stopped semaglutide and the lifestyle intervention that had accompanied the trial.

What did the STEP 1 extension find?

The extension followed 327 participants (228 who had received semaglutide 2.4 mg and 99 placebo) at selected sites. The semaglutide participants in this subset had lost an average of 17.3% of their starting weight by week 68. In the year after treatment and the trial's lifestyle support stopped, they regained an average of 11.6 percentage points, leaving a net mean reduction of 5.6% from baseline at week 120.

The authors described this as regaining roughly two-thirds of the prior weight loss. Cardiometabolic improvements also moved back toward baseline for many measures.

Does that mean everyone regains two-thirds?

No. These are group averages from a particular trial and extension subset, not a prediction for each individual. Individual results varied: at week 120, about half of the semaglutide participants with data (48.2%) still had at least 5% weight loss from baseline. The authors note the analyses were exploratory, with a relatively small sample from selected sites. People differ in treatment duration, underlying health, ongoing support, access, appetite, routines and other factors. The extension also stopped the trial's lifestyle intervention, which is important context when interpreting the results.

The study supports the idea that obesity can behave as a chronic condition and that ongoing treatment may be needed to maintain some benefits for many people. It does not mean a person should never stop, or that stopping without a plan will affect everyone the same way.

Why might weight return?

When a medicine that affects appetite and satiety is discontinued, its effects do not remain indefinitely. Hunger, food preoccupation and body-weight regulation can change again. After weight loss, the body can also respond in ways that make maintenance difficult. These factors are not personal failure or proof that earlier progress “didn't count.”

The details differ by medicine and person. Avoid assuming one semaglutide trial applies identically to tirzepatide or every GLP-1 product.

If you're thinking about stopping, what should you discuss?

Talk with the prescribing clinician before changing treatment. Useful questions include:

• Why am I considering stopping, and are there ways to address the reason?
• What health outcomes need monitoring if my treatment changes?
• How should we handle side effects, cost or supply interruptions?
• What support is available for appetite, nutrition, mental health and weight maintenance?
• What should I do if symptoms return or weight changes significantly?

Don't taper, stretch doses, restart or swap medicines on your own based on a social post or internet schedule. If a taper or pause is being considered, plan it with your prescriber. Different products have different instructions and risks.

What about food noise after stopping?

Some people report returning cravings or more frequent thoughts about food; others describe a different experience. Research on these subjective experiences is still developing. If returning food thoughts feel distressing, discuss them with a clinician rather than treating them as evidence that you lack willpower.

The emotional side deserves attention too

People may feel fear, grief, guilt or frustration when a treatment becomes unaffordable or no longer suits them. Online stories can make it seem as though everyone must maintain the same outcome forever. Clinical data describe groups, not a verdict on one person's future.

The useful focus is a sustainable, medically informed plan, not blame.

The takeaway

The STEP 1 extension found substantial average regain during the year after semaglutide and trial lifestyle intervention stopped, but outcomes vary. It is an important part of the conversation about long-term treatment, access and maintenance—not a reason to make medication decisions without medical support.

GLPily can help you keep a record of weight trends, symptoms and medication history to discuss with your care team.